NASDAQ:EXOZ eXoZymes Q1 2026 Earnings Results & Report $4.56 -0.04 (-0.76%) As of 09:42 AM Eastern This is a fair market value price provided by Massive. Learn more. eXoZymes reported Q1 2026 earnings on May 14, 2026. The company reported EPS of -$0.28. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 14, 2026TimeAfter Market ClosesConference Call4:00 PM ET eXoZymes EPS ResultsActual EPS-$0.28Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AeXoZymes Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) eXoZymes Q1 2026 Earnings FAQ Did eXoZymes beat earnings estimates for Q1 2026? eXoZymes (NASDAQ:EXOZ) reported earnings of -$0.28 per share for Q1 2026. The report was announced on Thursday, May 14, 2026. eXoZymes Earnings HeadlineseXoZymes Highlights Investor Presentation for Capital Markets OutreachOctober 9, 2026 | tipranks.comeXoZymes (NASDAQ:EXOZ) Shares Climb 6.1% - Should You Buy?October 3, 2026 | americanbankingnews.comI have publicly predicted six major American crashes, before each one happened.Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 14 at 1:00 AM | Weiss Ratings (Ad)eXoZymes Completes New Securities Offering to Fund PipelineJuly 1, 2026 | tipranks.comeXoZymes Secures NIH Grant to Advance Cannabinoid PipelineJune 26, 2026 | tipranks.comeXoZymes Completes Nasdaq Equity Offering to Fund PipelineJune 17, 2026 | tipranks.comSee More eXoZymes Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like eXoZymes? Sign up for Earnings360's daily newsletter to receive timely earnings updates on eXoZymes and other key companies, straight to your email. Email Address About eXoZymeseXoZymes (NASDAQ:EXOZ), Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.View eXoZymes ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
